See also: Fat Loss Peptides: The Complete Guide to AOD-9604, CJC-1295, and Tesamorelin — how AOD-9604 fits into the full fat loss peptide stack alongside CJC-1295/Mod-GRF and Tesamorelin, with protocols and evidence comparison.

AOD-9604: The Fat Loss Peptide That Targets Stubborn Body Fat

When the Scale Stops Moving

You've dialed in the diet. Macros are tracked. Training is consistent. Sleep is locked at seven-plus hours. Cardio sessions are in the calendar. And somewhere around the 12% body fat mark — or whatever your stubborn-fat threshold turns out to be — the scale stops moving and the mirror stops changing.

This is the wall most lean-out efforts hit. The visceral fat mobilizes early. The subcutaneous fat across the lower abdomen, lower back, hips, and thighs holds on with frustrating tenacity. Caloric deficits get harder to maintain because the body fights back: leptin drops, NEAT decreases, hunger signaling intensifies, and the metabolic adaptation curve flattens out the deficit you thought you were creating.

The pharmaceutical answer to this problem has historically been recombinant human growth hormone (hGH). It works — hGH is a potent lipolytic agent — but it brings a long list of systemic effects that have nothing to do with fat loss: elevated IGF-1, fluid retention, joint pain, insulin resistance, and a price tag that makes it a non-starter for most people.

In the late 1990s, a research team in Melbourne, Australia asked a different question: what if you could keep the fat-burning effects of hGH and discard everything else? The answer they engineered is AOD-9604 — Anti-Obesity Drug 9604 — a synthetic peptide built from the tail end of the hGH molecule. It is not growth hormone. It is the fat-metabolism fragment of growth hormone, isolated and reproduced in a form your body can use without the systemic spillover.

This article is a clinical look at what AOD-9604 actually is, how it works at the receptor level, what the human trials showed, how it stacks up against full hGH, and how it's used in current research protocols.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone — specifically, amino acids 177 through 191 of the hGH molecule, with a tyrosine residue added at the N-terminus to improve stability. It is sometimes referred to in the literature as hGH 176–191 or hGH 177–191 depending on numbering convention. The result is a 16-amino-acid peptide that retains a very specific subset of hGH's biological activity.

Full-length human growth hormone is a 191-amino-acid protein. It does many things in the body: it stimulates linear growth in children, promotes protein synthesis in muscle, increases IGF-1 production in the liver, antagonizes insulin, drives lipolysis in adipose tissue, and influences a host of other metabolic processes. For an adult who already finished growing and just wants to lose fat, most of those effects are either irrelevant or actively unwanted.

Researchers at Monash University and Metabolic Pharmaceuticals identified that the lipolytic (fat-mobilizing) and anti-lipogenic (fat-storage-blocking) actions of hGH appeared to be concentrated in the C-terminal region of the molecule. The growth-promoting and IGF-1-stimulating activity, by contrast, was concentrated elsewhere — primarily in the central region that binds the GH receptor.

By isolating the C-terminal fragment, researchers produced a molecule that:

• Retains the fat-burning signaling of hGH at adipocytes (fat cells).
• Eliminates the systemic growth signaling — no IGF-1 spike, no linear growth signaling, no anabolic-on-everything effect.
• Eliminates the blood-glucose elevation that comes with full hGH (because hGH antagonizes insulin; the C-terminal fragment does not).

That is the entire design thesis behind AOD-9604: take the part of growth hormone that burns fat, and leave the rest behind. For a deeper background on how peptides relate to the larger endocrine system, see our primer on peptides and hormones.

Mechanism of Action

AOD-9604 works through three primary, well-documented mechanisms in adipose tissue.

1. Stimulation of Lipolysis

Lipolysis is the process by which stored triglycerides in fat cells are broken down into free fatty acids and glycerol, which are then released into circulation and either oxidized for energy or repackaged. AOD-9604 directly stimulates this process. Preclinical studies in rodent models showed dose-dependent increases in lipolytic activity in adipose tissue when AOD-9604 was administered, with effects that mirror those of full-length hGH at comparable signaling endpoints — but without binding to the GH receptor itself.

2. Inhibition of Lipogenesis

Lipogenesis is the opposite process: the conversion of carbohydrate and other substrates into triglycerides for storage. AOD-9604 has been shown to inhibit lipogenic enzyme activity in adipose tissue, meaning less new fat is being deposited even as more existing fat is being mobilized. This bidirectional effect — burn more, store less — is the same dual action that makes hGH effective for body composition, replicated at the fragment level.

3. Beta-3 Adrenergic Receptor Activation

The beta-3 adrenergic receptor (β3-AR) is the dominant adrenergic receptor in adipose tissue and is heavily implicated in lipolytic signaling and thermogenesis. Animal data suggests AOD-9604 increases β3-AR expression and activity in adipose tissue, which amplifies the lipolytic response and may contribute to a modest increase in resting energy expenditure. β3-AR activation is the same general pathway exploited by certain pharmaceutical and supplement-based fat-loss agents (yohimbine, mirabegron, and a class of investigational β3 agonists), though AOD-9604 reaches it via a different route.

Why It Doesn't Affect IGF-1 — And Why That Matters

This is the part that distinguishes AOD-9604 from essentially every other GH-related compound on the research market. Full hGH and GH secretagogues like CJC-1295 and ipamorelin all eventually drive IGF-1 elevation through hepatic GH receptor activation. AOD-9604 does not. Because it does not bind the GH receptor in the same way as full hGH, it does not trigger the JAK/STAT signaling cascade that produces IGF-1 in the liver.

In human trials, AOD-9604 administration produced no measurable increase in serum IGF-1 levels at therapeutic doses. This matters for three reasons:

1. Glucose regulation. Elevated IGF-1 and elevated GH together can cause insulin resistance and hyperglycemia in susceptible individuals. AOD-9604 sidesteps this entirely. Trial data shows no clinically meaningful effect on fasting glucose or insulin sensitivity.
2. Theoretical cancer risk. Chronically elevated IGF-1 has been associated in some epidemiological data with increased risk of certain cancers (the data is mixed and not conclusive, but the concern exists). A fat-loss peptide that does not move IGF-1 takes that question off the table.
3. Tissue effects. Sustained IGF-1 elevation drives growth signaling in many tissues — including soft tissue, organs, and connective structures. The classic side effects of long-term hGH use (carpal tunnel symptoms, joint pain, fluid retention, organ enlargement at very high doses) are largely IGF-1- and GH-mediated. AOD-9604 produces none of these.

In short: same fat-loss mechanism at the adipocyte, none of the systemic spillover. That is the entire pharmacological argument for using a fragment instead of the parent molecule.

Want to see how AOD-9604 fits into a full performance stack? The Peptide Stacking Guide: Advanced Protocols covers complete protocols for body composition, recovery, and longevity.

Research History

AOD-9604 has a longer and more rigorous research record than most peptides currently used in performance and biohacking circles.

The compound was developed by Metabolic Pharmaceuticals, an Australian biotech based in Melbourne, in collaboration with researchers at Monash University. Development began in the late 1990s, building on earlier work characterizing the lipolytic activity of the hGH C-terminal fragment.

Between 2001 and 2010, Metabolic Pharmaceuticals conducted a full clinical development program for AOD-9604 as an anti-obesity drug:

• Phase I trials established a clean safety profile in healthy adults across a range of single and multiple ascending doses.
• Phase II trials in obese subjects assessed efficacy as a weight-loss agent. The results showed a modest but statistically real reduction in body fat at the doses studied (typically 1 mg daily, oral or subcutaneous depending on the trial), with the strongest effects in subjects who were heavier at baseline.
• Phase IIb data continued to support the safety profile and showed continued separation from placebo on body composition endpoints, though the absolute magnitude of effect was modest in the timeframes studied.

The drug was eventually granted GRAS (Generally Recognized As Safe) status by an independent expert panel in the United States in 2014, based on the accumulated safety data from the clinical program.

Despite the clean safety record, Metabolic Pharmaceuticals ultimately shelved the commercial drug program. The reasons were commercial rather than safety-related: the magnitude of weight loss in the obese-population trials was real but modest compared to what the regulatory and reimbursement landscape would have required for a successful obesity drug launch. The bar for an obesity pharmaceutical is high (and has only gotten higher with the arrival of GLP-1s like semaglutide and tirzepatide), and a drug producing modest fat loss without the dramatic effects of those newer agents had a difficult commercial path.

What that left behind, however, was a peptide with:

• A complete Phase I–II safety dataset in humans.
• GRAS status reflecting that safety record.
• A well-characterized mechanism of action.
• No regulatory approval as a marketed drug, and therefore current availability only as a research peptide.

For researchers and biohackers, that combination is unusual. Most peptides used outside of pharmaceutical channels have far less clinical data behind them.

AOD-9604 vs. hGH for Fat Loss

If the goal is targeted fat loss specifically — not muscle gain, not anti-aging, not recovery — the comparison between AOD-9604 and full recombinant hGH is one of the most important to understand.

The summary: hGH does more, including the things you don't want. AOD-9604 does one thing — fat metabolism — and does it without the systemic baggage. For someone whose only goal is body recomposition and stubborn-fat reduction, the fragment is the more surgical tool.

This is also why AOD-9604 doesn't show up in conversations about the best peptides for muscle growth. It's not anabolic. It doesn't raise IGF-1. It doesn't drive protein synthesis. It is, by design, a single-purpose molecule.

Protocols

Research-literature dosing for AOD-9604 has converged on a fairly narrow range over the years.

Standard Dosing

• Dose: 300–500 mcg per day, subcutaneous injection.
• Route: SubQ, typically into abdominal adipose tissue (some protocols rotate to thigh or flank).
• Frequency: Once daily.
• Cycle length: 8–12 weeks is the most common range cited in the research literature, with some longer continuous protocols documented in the original Phase II trials.

Timing

AOD-9604 is most commonly dosed in a fasted state, either:

• First thing in the morning, 30–45 minutes before breakfast, or
• Pre-workout on training days, in a fasted state.

The fasted-state recommendation is based on two considerations. First, lipolytic signaling is generally more effective when insulin is low — insulin is the primary anti-lipolytic hormone, so administering a lipolytic peptide while insulin is elevated post-meal blunts the effect. Second, peptide absorption from a SubQ depot is cleaner in a fasted, low-circulating-substrate state.

If you're combining AOD-9604 with fasted morning cardio or fasted training, the timing dovetails naturally — dose, wait 20–45 minutes, train.

Reconstitution

AOD-9604 ships as a lyophilized (freeze-dried) powder, usually in 2 mg or 5 mg vials. It is reconstituted with bacteriostatic water or sterile water depending on intended storage duration. The general approach is the same as for other peptides — gentle injection of solvent down the side of the vial, no shaking, gentle swirl to dissolve. For step-by-step technique and dose-math, see our reconstitution guide.

Reconstituted AOD-9604 should be refrigerated. Lyophilized vials are stable at refrigerator temperatures and tolerate brief room-temperature shipping; long-term storage of unreconstituted vials at -20°C is preferable for protocols longer than a few weeks. For temperature-and-stability specifics across peptides, our storage and temperature guide covers the details.

Stacking

AOD-9604's narrow mechanism makes it a clean stacking candidate. Because it doesn't move IGF-1, doesn't affect glucose, and doesn't push the same receptor systems as most other peptides, it can usually be added to an existing protocol without confounding signals.

AOD-9604 + CJC-1295 / Ipamorelin

This is the most common stack in body-composition protocols. The logic is mechanistic complementarity:

• CJC-1295 / Ipamorelin drive endogenous GH pulses, which produce systemic anabolic signaling, IGF-1 elevation, and improved recovery and sleep.
• AOD-9604 adds a direct lipolytic signal at the adipocyte without further amplifying the IGF-1 axis.

The combined effect is broader than either alone — GH-pulse benefits (recovery, body composition, sleep depth) layered with targeted fat-loss signaling. For the comparison between the two GH secretagogues that anchor this stack, see Ipamorelin vs. CJC-1295.

AOD-9604 + BPC-157

This is a body-recomposition-and-recovery stack. BPC-157's effects are concentrated on tissue repair, gastrointestinal integrity, and connective-tissue healing, while AOD-9604 handles the fat-metabolism side. For users running aggressive training while in a deficit, the combination addresses the two main failure modes of hard cutting: stalled fat loss and accumulating injury risk. For BPC-157 background, see BPC-157 benefits.

AOD-9604 + Tirzepatide / GLP-1 Agonists

This is a more recent and increasingly common context. The biohacker audience that's been reading about GLP-1 receptor agonists (semaglutide, tirzepatide) is well aware that those compounds drive substantial weight loss but don't selectively target body fat — lean mass loss is a documented concern in unsupervised GLP-1 use, and the fat-loss is generalized rather than targeted to stubborn depots.

In that context, AOD-9604 is sometimes layered in for targeted fat mobilization alongside the appetite-and-energy-balance effects of the GLP-1. It does not modify the GLP-1's mechanism — it adds a separate lipolytic signal on top of an existing caloric deficit. This is mechanistic stacking, not a pharmacological interaction concern.

For a broader discussion of how peptide stacks are constructed and what considerations apply when combining compounds, our paid Peptide Stacking Guide: Advanced Protocols covers complete body-composition, recovery, and longevity stacks in detail.

Side Effects & Safety

AOD-9604's safety profile is one of the cleanest in the research-peptide space, which is a direct consequence of the unusually complete clinical development record.

What the trials reported

Across Phase I and Phase II trials in healthy and obese subjects:

• The compound was generally well tolerated.
• Adverse events were typically mild, transient, and not clearly distinguishable from placebo at standard doses.
• The most commonly reported issues were mild injection site reactions (transient redness or tenderness) and occasional transient nausea in the early phase of dosing.

What was not observed

• No carcinogenicity signal in animal studies at therapeutic-equivalent doses.
• No hypoglycemia — AOD-9604 does not push insulin secretion or sensitize tissues to insulin, and it does not antagonize insulin the way full hGH does. Glucose effects have been clinically silent.
• No androgenic effects — AOD-9604 does not interact with sex hormone receptors and does not modify testosterone, estrogen, or related markers.
• No water retention or joint symptoms of the type associated with hGH use.

GRAS status and current regulatory context

AOD-9604 received Generally Recognized As Safe status from an independent expert panel in 2014, based on the accumulated clinical safety record. GRAS is a US regulatory designation typically applied to food ingredients; in this case, it reflects the underlying safety dataset rather than any food-product use. It is not the same as FDA approval as a drug — Metabolic Pharmaceuticals never sought drug approval after shelving the commercial program.

In current practice, AOD-9604 is sold and used for research purposes only. It is not a prescription drug, not an approved supplement, and not legal to market for human use. The safety record is favorable; the legal status is research-only. For a broader discussion of peptide side-effect profiles and what to monitor across compounds, see our peptide side effects guide.

Who Is It For?

AOD-9604 is a narrow tool. It does one thing well. The people who tend to get the most out of it are:

• Body recompers who've plateaued. Lean trainees who have already pushed nutrition and training hard, hit a stubborn-fat wall, and want a targeted lipolytic signal layered onto an already-dialed-in protocol. AOD-9604 is not a substitute for a deficit; it's an amplifier on top of one.
• Biohackers stacking with GH secretagogues. People already running CJC-1295/ipamorelin or similar protocols for the GH-pulse benefits, looking to add a clean fat-loss vector without adding more IGF-1 signaling on top of an already-elevated baseline.
• People who want the fat-loss angle of hGH without the cost or systemic exposure. This is the largest cohort. Full hGH is expensive, requires careful monitoring of IGF-1 and glucose, and produces a long list of side effects most users don't want. AOD-9604 captures the fat-loss component at a fraction of the cost and with a much smaller footprint of systemic effect.
• GLP-1 users looking to bias fat loss toward fat. Those running semaglutide or tirzepatide for body-composition goals who want to add a targeted lipolytic signal alongside the appetite suppression.

AOD-9604 is not a good choice for someone primarily interested in muscle gain, recovery, anti-aging, or general performance — its mechanism is too narrow. It's also not a magic bullet for the unmotivated; the trials that produced its modest effect size did so against a background of caloric restriction. Without the deficit, the lipolytic signal has nothing to act on.

Conclusion

The core idea behind AOD-9604 is unusual in peptide research: take a complex, multi-action endogenous hormone, identify the precise fragment responsible for the effect you want, and engineer a synthetic version of that fragment alone. The result is a peptide that delivers the fat-loss signaling of human growth hormone without the IGF-1 elevation, glucose dysregulation, water retention, joint symptoms, or cost of the parent molecule.

That surgical narrowness is both the strength and the limit of AOD-9604. It is not anabolic. It is not regenerative. It does not address recovery, sleep, libido, immune function, or any of the other endpoints that other peptides target. What it does is provide a clean, well-tolerated, well-studied lipolytic signal at the adipocyte — a single, sharp tool for the specific problem of stubborn body fat in a trainee who already has the rest of the picture in order.

For anyone who has spent months chasing the last few percentage points of body fat through diet and training alone, that surgical narrowness is exactly the point.

Ready to build your knowledge base? Grab the Peptide 101: Complete Bundle — beginner's guide + advanced stacking protocols, everything you need in one package.

This article is for educational and research purposes only. AOD-9604 is not approved by the FDA as a drug for human use. The information here is a summary of published research and should not be interpreted as medical advice. Consult a qualified clinician before initiating any peptide protocol.